Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

Inclusion Criteria: * Voluntarily participate in the clinical study * Aged ≥ 18 years at the time of signing the informed consent form * Histologically or cytologically confirmed early-stage T1-3 N0 NSCLC, or patients with multiple primary lesions or solitary pulmonary parenchymal recurrence * Confirmed presence of EGFR-sensitive mutations by genetic testing, including but not limited to Exon 19 deletion, L858R, G719X, L861Q, S768I, and their compound mutations * ECOG performance status score of 0-2 * Deemed medically inoperable or refuse surgery after multidisciplinary evaluation * Pulmonary lesions suitable for ablation or radiotherapy (either modality) * Adequate major organ function Exclusion Criteria: * Known severe allergic reaction (NCI-CTCAE v5.0 grade ≥ 3) to any monoclonal antibody or any excipient of the study drug * Known contraindications to ablation or radiotherapy * Failure to meet the minimum requirements for target coverage and dose constraints to organs at risk in the SABR treatment plan * Active infection requiring systemic anti-infective therapy within 14 days prior to the first dose * Patients with hepatitis B (hepatitis B surface antigen \[HBsAg\] positive and detectable HBV-DNA indicating viral replication); hepatitis C (hepatitis C virus \[HCV\] antibody positive and detectable HCV-RNA indicating viral replication) * Receipt of curative-intent radiotherapy within 3 months prior to the first dose * Major surgery within 28 days prior to the first dose…